Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc. “They’ve achieved one of the rare things in our space where you actually have ...

Financing was provided by Ares Management Credit funds. Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. This press release ...

Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Tempus AI announced today it is acquiring genetic ...

Third Quarter 2024 Financial Results Additional Operating Highlights Ambry Genetics Acquisition Tempus today announced that it has entered into an agreement to acquire Ambry Genetics, a leader in ...

Shares of Tempus AI TEM gained 18.4% after it announced an agreement, on Nov. 4, 2024, to acquire Ambry Genetics for $600 million. This acquisition will likely help Tempus revolutionize healthcare ...

Tempus AI (NASDAQ:TEM) saw its stock decline by 4% after short-selling firm Spruce Point Capital released a scathing report ...

Aliso Viejo-based Ambry Genetics Corp., Orange County’s third-largest medical diagnostics and testing company, has entered into an agreement to be acquired for $600 million by Tempus AI Inc., which is ...